Description: IDT Australia Limited is engaged in the supply of products and provision of research and development and other technical services for the pharmaceutical and allied industries. The Company's segments include CMAX, Boronia and Corporate/Unallocated. Its CMAX is a clinical trial facility in Adelaide, South Australia. It has an integrated manufacturing, development and corporate facility at Boronia, Victoria. The Company specializes in manufacture of active pharmaceutical ingredients (API) and finished dose products, including beta lactams; microbiological and analytical testing; clinical packaging, and Phase I and first time in man clinical trials research and pharmacy services. Its IDT Pharma specializes in the development, scale-up and current goods manufacturing practices (cGMP) clinical and commercial manufacture of cytotoxic API and finished drug product. The Company also offers a range of clinical trial labelling, packaging and dispensing services.
Home Page: en.idtaus.com.au
IDT Technical Analysis
45 Wadhurst Drive
Boronia,
VIC
3155
Australia
Phone:
61 3 9801 8888
Officers
| Name | Title |
|---|---|
| Mr. Paul McDonald | Interim CEO |
| Mr. Chris Kagiaros | Head of People & Culture |
| Dr. David Sparling BVSc (Hons), GDipAppCGov, L.L.B., LLB (Hons) | Joint company Sec. |
| Mr. Vasanthakumar Mahendran | Interim Chief Financial Officer |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.768 |
| Price-to-Sales TTM: | 1.5697 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |